🔗 Share this article

An underground market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.

Investigational Drug Acquiring Traction Online

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Viewers are urged to contact these profiles directly for source information, while also obtaining discount codes.

Active Trade on Social Networks

Additionally, a flourishing trade exists on Telegram, where communities with numerous of members share “before and after” images, administration instructions and claims of rapid British shipping. Vendors market the substance there before redirecting buyers to WhatsApp for transactions.

Understanding Retatrutide

Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could help individuals lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Medical Professionals Express Worries

Nevertheless, physicians and chemists have warned that the sale of what is still an unlicensed drug in the United Kingdom is a cause for concern and could lead to individuals injecting substances of uncertain source.

Several professionals said the demand for retatrutide could be linked to the rising cost of licensed weight loss products such as Mounjaro.

Legal Position and Implementation

Selling retatrutide on TikTok or Telegram is prohibited in the United Kingdom, as it is an unapproved medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still violate medicines, marketing, and consumer laws, risking fines, prosecution or prison.

Platform Response and Content Elimination

According to the social media company, the platform has removed problematic material and prohibited related keywords and search suggestions. The company said it was dedicated to maintaining the platform safe and allocating resources in enhancing enforcement strategies.

Online Marketplace Operations

Investigations also discovered groups with up to 9,000 participants marketing retatrutide using the platform's built-in search feature, which operates like a online catalog. Typing “retatrutide” immediately brings up groups with thousands of members, populated with photos of weight loss, positive reviews and step-by-step guides for mixing or injecting at residence.

After moments of entering one group, a vendor shared contact information, where most purchases take place. The vendor sent an instruction manual and promised shipping within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None asked about body mass, health issues or previous experience.

Product Details and Pricing

Inside these groups, posts display black plastic parcels with Royal Mail stickers, claiming to include new batches. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with sterile water, or ready-to-use pens typically sold at £160 for 20mg. When questioned how long a injector should last, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Service Oversight and Security Actions

A representative for Telegram stated it regularly moderated dangerous material on its service including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“Individuals are administering materials they cannot confirm. Although the science behind this drug is sound, these digital versions may not contain what they advertise,” said Jason Murphy, the director of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the increase in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, patients are using social media. But fake treatments are highly dangerous. You cannot know what’s contained or whether the environment they were made in was sterile,” she said.

Her team has previously seen patients harmed by self-injection from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These substances could be contaminated or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any government authority globally. “Therefore at this point no one can market [it] for personal consumption,” they said, adding that any item “falsely representing itself as a Lilly investigational substance not yet approved … may expose patients to possibly significant medical dangers”.